Table 3. ORR Subgroup Analysis in the Efficacy-Evaluable Population.

Patient Subgroup	No./Total No. of Patients	ORR, % (90% CI)a
All	11/60	18 (11-29)
Platinum status
Resistant	6/29	21 (9-37)
Refractory	2/16	13 (2-34)
Not applicableb	3/15	20 (6-44)
Prior lines of therapyc
1-2	7/25	28 (14-46)
≥3	4/35	11 (4-24)
Prior bevacizumab use
Yes	7/37	19 (9-33)
No	4/23	17 (6-36)
tBRCA statusd
tBRCAmut	2/11	18 (3-47)
tBRCAwt	9/47	19 (10-31)
PD-L1 statusd
Positive	7/33	21 (10-36)
Negative	2/21	10 (2-27)
HRD statusd
HRD positive	3/21	14 (4-33)
HRD negative	6/32	19 (9-34)

Abbreviations: HRD, homologous recombination deficiency; ORR, objective response rate; PD-L1, programmed death-ligand 1; tBRCA, tumor BRCA; tBRCAmut, tumor BRCA mutation; tBRCAwt, tumor BRCA wild type.

^aIncludes only confirmed responses using Response Evaluation Criteria in Solid Tumors, version 1.1.

^bIncludes patients with an interval free of platinum-based chemotherapy of at least 180 days but unable to receive further platinum-based chemotherapy (owing to toxic effects or allergic reaction).

^cFor pooled analysis, neoadjuvant therapy, adjuvant therapy, and the combination of both were considered to be 1 line of therapy. Small molecules, hormonal agents, and bevacizumab were not counted in the lines of therapy.

^dOnly patients with known biomarker status were included.